Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study

Publisher： John Wiley & Sons Inc

E-ISSN： 1423-0410|113|2|120-127

ISSN： 0042-9007

Source： VOX SANGUINIS, Vol.113, Iss.2, 2018-02, pp. : 120-127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial

By  

TRANSFUSION, Vol. 58, Iss. 2, 2018-02 ,pp. : 413-422

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 16, Iss. 2, 2018-02 ,pp. : 253-261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Molecular Basis of Fibrinogen Deficiency

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 35, Iss. 1-2, 2006-06 ,pp. : 187-198

Karger

Access to resources Recommend Favorite

Use of fibrinogen concentrate in bleeding patients

By  

ANAESTHESIA, Vol. 3-2409, Iss. 11, 2015-11 ,pp. : 1323-1324

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of fibrinogen concentrate in bleeding patients

By  

ANAESTHESIA, Vol. 70, Iss. 11, 2015-11 ,pp. : 1323-1324

John Wiley & Sons Inc

Access to resources Recommend Favorite